US 10,300,055 B2Granted

Treatment of parkinson's disease through ARFGAP1 inhibition

AssigneeDalhousie University

InventorsMichel Roberge, Chris McMaster, Carla Zimmerman, Pak Poon

Life of this patent

Estimating the term…

Abstract

Methods are provided for the treatment of Parkinson's disease (PD) in patients bearing mutations in the LRRK2 gene. A therapeutically effective amount of piperazine derivative compounds are employed to inhibit the biological activity of ArfGAP1, inhibition that counteracts the deleterious effects of mutations in, or increased expression of, the LRRK2 protein.

Claims6

Dependent claims

A method of treating Parkinson's disease in a human subject in need thereof, comprising administering to the subject a compound having the formula:

Dependencies are inferred from the claim text.

Facts

Application: 15/302,930Filed 10 Apr 2015 · us provisional application
Priority: 10 Apr 2014
Published: US 2017/0020866 A126 Jan 2017
Granted: 28 May 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 31/495
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with two or more nitrogen atoms as the only ring…
A61K 31/381
Having sulfur as a ring hetero atom: having five-membered rings
A61K 31/4402
Non condensed pyridines; Hydrogenated derivatives thereof: only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 31/4425
Non condensed pyridines; Hydrogenated derivatives thereof: pyridinium derivatives, e.g. pralidoxime, pyridostigmine

Family

Application61/978,091Us provisional application · filed 10 Apr 2014
US 2017/0020866 A1Pre-grant publication · published 26 Jan 2017
US 10,300,055 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results